Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer

Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder cancers and is characterized by a high risk of recurrence and progression. Current guidelines recommend that patients with stage T1 NMIBC undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery to remove residual tumor, confirm staging, and obtain additional pathological information. However, the benefits of routine re-TURBT for all high-risk patients remain controversial, as many patients may not have residual disease, while the procedure

Trial Details

NCT ID
NCT07187635
Phase
NA
Sponsor
Tianjin Medical University Second Hospital
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • Second Transurethral Resection of Bladder Tumor (re-TURBT)
  • utDNA Testing (Urine Tumor DNA Detection)
Locations (sample)
  • Nanchang, Anhui, China
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Xingtai, Hebei, China|37.06217,114.49272
  • Kunming, Yunnan, China|25.03889,102.71833
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Participants must meet all of the following criteria to be eligible for the study:
  • Male or female, aged 18 years or older.
  • Histologically confirmed non-muscle-invasive bladder tumor, with no evidence of muscle-invasive bladder cancer or metastatic disease.
  • Histologically confirmed urothelial carcinoma of the bladder or bladder tumor with urothelial carcinoma as the predominant component (\>50%).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →